NCT04155190 2023-05-31
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Sol-Gel Technologies, Ltd.
Phase 2 Terminated
Sol-Gel Technologies, Ltd.
Stanford University
Novartis